Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting

TL;DR: Alice K. Jacobs,MD, FACC, FAHA, Chair Jeffrey L. Anderson, MD, F ACC, FAH, Chair-Elect Nancy Albert, PhD, CCNS, CCRN,FAHA, chair-Elect.

TL;DR: Postponing elective noncardiac surgery for two to four weeks after coronary stenting should permit completion of the mandatory antiplatelet regimen, thereby reducing the risk of stent thrombosis and bleeding complications.

TL;DR: Clopidogrel in combination with aspirin before CABG is associated with higher postoperative bleeding and morbidity, and these findings raise concern regarding the routine administration of clopidOGrel before anticipated coronary stent implantation.

TL;DR: It is concluded that aprotinin is extremely effective in reducing bleeding and transfusion requirements and may increase the risk of graft thrombosis.

TL;DR: Patients with adult respiratory distress syndrome and patients after cardiac surgery with cardiopulmonary bypass demonstrated changes consistent with membrane fragmentation without secretion: a decreased platelet surface concentration of GP Ib and GP IIb with no increase of GMP-140 and TSP, and an increased plasma concentration of platelet membrane microparticles.

TL;DR: The possibility that this problem might be alleviated by desmopressin acetate (DDAVP), which increases the plasma level of von Willebrand factor and improves hemostasis in mild hemophilia and other conditions associated with defective platelet function, is examined.

TL;DR: It is indicated that a low dose of aspirin (40 to 80 mg) can largely inhibit platelet aggregation and thromboxane synthesis but has much less effect on prostacyclin production in arterial and venous endothelium.

TL;DR: These data establish statistically significant prophylaxis against venous thromboembolism in men over the age of 40 by 600 mg of aspirin given twice daily, and the absence of a protective effect in women remains unexplained.